Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme ; volume:8 ; number:1 ; day:20 ; month:2 ; year:2013 ; pages:1-9 ; date:12.2013
Radiation oncology ; 8, Heft 1 (20.2.2013), 1-9, 12.2013
- Creator
-
Jastaniyah, Noha
- Contributor
-
Murtha, Albert
Pervez, Nadeem
Le, Duc
Roa, Wilson
Patel, Samir
Mackenzie, Marc
Fulton, Dorcas
Field, Colin
Ghosh, Sunita
Fallone, Gino
Abdulkarim, Bassam
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-8-38
- URN
-
urn:nbn:de:1111-201604098323
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
13.08.2025, 12:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jastaniyah, Noha
- Murtha, Albert
- Pervez, Nadeem
- Le, Duc
- Roa, Wilson
- Patel, Samir
- Mackenzie, Marc
- Fulton, Dorcas
- Field, Colin
- Ghosh, Sunita
- Fallone, Gino
- Abdulkarim, Bassam
- SpringerLink (Online service)
Other Objects (12)
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
Effects of chemotherapy with temozolomide on cell cycle associated proteins in glioblastoma multiforme
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report
Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single‑center Data
Ultrasound-activated nano-TiO2 loaded with temozolomide paves the way for resection of chemoresistant glioblastoma multiforme
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
Effects of chemotherapy with temozolomide on cell cycle associated proteins in glioblastoma multiforme
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report
Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single‑center Data
Ultrasound-activated nano-TiO2 loaded with temozolomide paves the way for resection of chemoresistant glioblastoma multiforme
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
Effects of chemotherapy with temozolomide on cell cycle associated proteins in glioblastoma multiforme
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report
Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single‑center Data
Ultrasound-activated nano-TiO2 loaded with temozolomide paves the way for resection of chemoresistant glioblastoma multiforme
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol